8-K: Precision BioSciences Reports Strong Q4, Extends Cash Runway

Precision BioSciences announced its Q4 and FY 2025 financial results, highlighting significant clinical progress in gene editing programs and an extended cash runway through 2028.

Summary

• Net income for the fourth quarter ended December 31, 2025, was $20.1 million, or $1.06 per share basic, a significant improvement from a net loss of ($17.8) million, or $(2.22) per share, in Q4 2024.
• Total revenues for Q4 2025 increased to $34.2 million from $0.6 million in Q4 2024, primarily due to revenue recognition from Novartis and Imugene agreements.
• For the full fiscal year 2025, the company reported a net loss of ($45.7) million, or ($3.56) per share, compared to a net income of $7.2 million, or $1.05 per share, in FY 2024.
• Cash, cash equivalents, and restricted cash stood at $137.2 million as of December 31, 2025, with an expected cash runway through 2028.
• The PBGENE-HBV Phase 1 ELIMINATE-B trial has dosed 13 patients across 5 cohorts, demonstrating safety, tolerability, and cumulative, dose-dependent antiviral activity, with data updates expected throughout 2026.
• PBGENE-DMD received IND clearance from the FDA, enabling the initiation of the Phase 1/2 FUNCTION-DMD trial, with initial data from multiple patients expected by year-end 2026.
• PBGENE-DMD was granted Fast Track designation and Orphan Drug Designation by the FDA.
• Partnered program iECURE-OTC achieved a complete clinical response in the first infant with neonatal onset OTC deficiency and received FDA Regenerative Medicine Advanced Therapy (RMAT) designation.
• Precision received an $8 million milestone payment from Imugene and a $7.5 million cash payment from TG Therapeutics related to Azer-Cel clinical and regulatory progress.
• The company successfully completed a $75 million underwritten offering in November 2025.
• Two Notices of Allowance were received from the U.S. Patent and Trademark Office for PBGENE-HBV, extending patent expiration to November 2044.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong clinical progress across multiple programs, significant milestone payments, and a strengthened financial position with an extended cash runway, despite a full-year net loss primarily due to prior year revenue recognition.

Positives

• Achieved a net income of $20.1 million in Q4 2025, a substantial turnaround from a net loss of ($17.8) million in Q4 2024.
• Total revenues for Q4 2025 significantly increased to $34.2 million from $0.6 million in Q4 2024, driven by milestone payments and revenue recognition.
• Extended expected cash runway through 2028, providing financial stability for multiple clinical inflection points.
• PBGENE-HBV Phase 1 data showed safety, tolerability, cumulative, dose-dependent antiviral activity, and molecular evidence consistent with viral DNA gene editing.
• Received IND clearance for PBGENE-DMD, allowing the initiation of the Phase 1/2 FUNCTION-DMD trial.
• PBGENE-DMD was granted Fast Track designation and Orphan Drug Designation by the FDA, potentially accelerating development and review.
• Partnered program iECURE-OTC achieved a complete clinical response in the first participant and received RMAT designation.
• Received $8 million in milestone payments from Imugene and $7.5 million in cash from TG Therapeutics for partnered programs.
• Successfully raised $75 million in an underwritten offering in November 2025, strengthening the financial position.
• Secured two new Notices of Allowance for PBGENE-HBV patents, extending intellectual property protection to November 2044.
• Decreased Research and Development expenses by $1.4 million in Q4 2025 and $5.4 million in FY 2025 due to program prioritization and preclinical cost reductions.
• Decreased General and Administrative expenses by $2.4 million in Q4 2025 and $3.1 million in FY 2025 due to operational discipline and lower employee-related costs.

Negatives

• Total revenues for the fiscal year 2025 decreased significantly to $34.3 million from $68.7 million in FY 2024, primarily due to prior year revenue recognition from concluded agreements.
• Reported a net loss of ($45.7) million for FY 2025, a decline from a net income of $7.2 million in FY 2024.
• Operating loss for FY 2025 increased to ($52.1) million from ($26.2) million in FY 2024.
• Total other income decreased by $27.8 million in FY 2025, mainly due to a decrease in gain in fair value of warrant liability and interest income.
• The PBGENE-HBV trial is investigating prophylactic measures to mitigate acute infusion reactions common to LNP-delivered therapies, such as transient hypotension and elevated liver enzymes.
• The collaboration with Novartis in the area of hemoglobinopathies has concluded.

Risks

• Ability to become profitable.
• Ability to procure sufficient funding to advance programs and raise additional capital due to market conditions and/or market capitalization.
• Risks associated with capital requirements, current debt instruments, and effects of restrictions thereunder.
• Operating expenses and the ability to predict those expenses.
• Limited operating history.
• The progression and success of programs and product candidates.
• Limited ability or inability to assess the safety and efficacy of product candidates.
• Risk that other genome-editing technologies may provide significant advantages over the ARCUS technology.
• Dependence on the ARCUS technology.
• The initiation, cost, timing, progress, achievement of milestones, and results of research and development activities and preclinical and clinical studies.
• Public perception about genome editing technology and its applications.
• Competition in the genome editing, biopharmaceutical, and biotechnology fields.
• Ability to identify, develop, and commercialize product candidates.
• Pending and potential product liability lawsuits and penalties.
• The U.S. and foreign regulatory landscape applicable to development of product candidates.
• Ability to advance product candidates into, and successfully design, implement, and complete, clinical trials.
• Potential manufacturing problems associated with the development or commercialization of any product candidates.
• Delays or difficulties in enrolling patients.
• Changes in interim top-line and initial data.
• Product candidates not working as intended or causing undesirable side effects.
• Risks associated with applicable healthcare, data protection, privacy, and security regulations and compliance therewith.
• Ability to obtain orphan drug designation or fast track designation for product candidates or to realize the expected benefits of these designations.
• Ability to obtain and maintain regulatory approval of product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate.
• The rate and degree of market acceptance of any product candidates.
• Ability to effectively manage the growth of operations.
• Ability to attract, retain, and motivate executives and personnel.
• Effects of system failures and security breaches.
• Insurance expenses and exposure to uninsured liabilities.
• Effects of tax rules.
• Effects of any pandemic, epidemic, or outbreak of an infectious disease.
• The success of existing collaboration and other license agreements, and the ability to enter into new collaboration arrangements.
• Current and future relationships with and reliance on third parties including suppliers and manufacturers.
• Ability to obtain and maintain intellectual property protection for technology and any product candidates.
• Potential litigation relating to infringement or misappropriation of intellectual property rights.
• Effects of natural and manmade disasters, public health emergencies, and other natural catastrophic events.
• Effects of sustained inflation, supply chain disruptions, and major central bank policy actions.
• Market and economic conditions.
• Risks related to ownership of common stock, including fluctuations in stock price.
• Ability to meet the requirements of and maintain listing of common stock on Nasdaq or other public stock exchanges.

Future Outlook

Precision BioSciences expects to release additional clinical biomarker and biopsy data for PBGENE-HBV in the first half of 2026, with further clinical data presentations at medical conferences throughout 2026. The company anticipates completing dosing in PBGENE-HBV Cohorts 3, 4, and 5 to inform optimal dosing regimen selection. Initial data from multiple PBGENE-DMD patients, including safety and early efficacy, is expected by year-end 2026. Partner iECURE expects to release additional data from the OTC-HOPE clinical trial in the first half of 2026. TG Therapeutics is expected to present preliminary Phase 1 azer-cel data in progressive multiple sclerosis in the second half of 2026 and commence additional exploratory studies in autoimmune diseases in 2026. The company projects its existing cash and cash equivalents, inclusive of expected milestone proceeds, will fund its cash runway through 2028.

Management Comments

• "2025 was an exceptional year for Precision BioSciences marked by meaningful clinical and financial progress. We delivered on what we committed to achieve and more in 2025 positioning Precision BioSciences for success in 2026 and beyond."
• "The evidence supporting the clinical utility of ARCUS for in vivo gene editing continues to mount in diseases with high unmet need led by advancement of PBGENE-HBV through multiple cohorts in our ELIMINATE-B study for chronic hepatitis B."
• "In another first, our partner iECURE achieved a complete response in the first infant with neonatal onset OTC deficiency following treatment with ECUR-506 which utilizes an ARCUS nuclease developed by Precision for in vivo gene insertion."
• "Finally, we strengthened our financial position by extending our expected cash runway through 2028 and entered 2026 focused on achieving multiple potential clinical value-inflection points for PBGENE-HBV and PBGENE-DMD this year."

Industry Context

StockSavvy.ai notes that Precision BioSciences' progress in gene editing, particularly with its ARCUS platform, positions it within a highly competitive and rapidly evolving biotechnology landscape. The focus on in vivo gene editing for high unmet need diseases like chronic Hepatitis B and Duchenne muscular dystrophy aligns with broader industry trends towards curative therapies. The successful clinical advancements and strategic financing demonstrate the company's ability to attract investment and execute on its pipeline, a critical factor for clinical-stage biotechs.

Comparison to Industry Standards

• The complete clinical response in the first infant with neonatal onset OTC deficiency for ECUR-506 (partnered with iECURE) is a significant early indicator, comparable to other pioneering gene therapy successes in rare genetic diseases.
• The Fast Track and Orphan Drug designations for PBGENE-DMD align with regulatory support often granted to therapies addressing severe, life-threatening conditions with limited treatment options, similar to other DMD programs by Sarepta Therapeutics (e.g., Elevidys) or Pfizer (e.g., for Duchenne).
• The extension of cash runway through 2028, following a $75 million raise, provides a longer financial horizon than many early-stage biotech companies, allowing for sustained clinical development without immediate dilution pressure, a benchmark for financial stability in the sector.
• The reported safety and dose-dependent antiviral activity of PBGENE-HBV in Phase 1, with evidence of viral DNA gene editing, positions it uniquely against other HBV therapeutic approaches that primarily focus on HBsAg suppression, such as those from Gilead Sciences or Arbutus Biopharma, by targeting the cccDNA.

Stakeholder Impact

• Shareholders: Potential for increased value due to clinical progress, extended cash runway, and new patent protection, balanced against dilution from the recent capital raise.
• Patients (HBV, DMD, OTC, MS): Hope for new, potentially curative treatments with ongoing clinical trials and positive early data.
• Employees: Continued employment and focus on advancing the pipeline with a strengthened financial position.
• Partners (iECURE, Imugene, TG Therapeutics): Continued collaboration and achievement of milestone payments, validating their investments.
• Creditors: Improved financial stability with an extended cash runway, enhancing the company's ability to meet its obligations.

Next Steps

• Complete dosing in PBGENE-HBV Cohorts 3, 4, and 5 to inform selection of an optimal dosing regimen.
• Share additional clinical biomarker and biopsy data for PBGENE-HBV in the first half of 2026.
• Present further clinical data from the PBGENE-HBV program at hepatitis-focused medical conferences throughout 2026.
• Initiate Institutional Review Board (IRB) activities and clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical trial.
• Expect initial data from multiple PBGENE-DMD patients, including safety and early efficacy assessment, by year-end 2026.
• Host a KOL event on March 17th to provide an overview of PBGENE-DMD and the FUNCTION-DMD Phase 1/2 clinical trial.
• iECURE expects to release additional data from the ongoing OTC-HOPE clinical trial in the first half of 2026.
• TG Therapeutics expects to present preliminary Phase 1 azer-cel data in progressive multiple sclerosis in the second half of 2026.
• TG Therapeutics expects commencement of additional exploratory studies in autoimmune diseases outside of multiple sclerosis in 2026.

Key Dates

Recommendation

Precision BioSciences demonstrates significant clinical progress across its gene editing pipeline, particularly with positive early data for PBGENE-HBV and the advancement of PBGENE-DMD into the clinic with Fast Track designation. The extended cash runway through 2028 provides crucial financial stability. However, the full-year financial results show a substantial net loss compared to the prior year, and the company remains in a clinical stage with inherent risks associated with drug development. While the long-term potential is promising, the stock is a "hold" for now, awaiting further de-risking clinical data and a clearer path to profitability.

Keywords

Gene editing, ARCUS, PBGENE-HBV, Hepatitis B, PBGENE-DMD, Duchenne muscular dystrophy, DMD, iECURE-OTC, OTC deficiency, Azer-Cel, CAR T, Multiple Sclerosis, Financial results, Clinical trials, Biotechnology, Nasdaq, DTIL, FDA, IND, Fast Track, Orphan Drug, RMAT